{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:59:24Z","timestamp":1793239164271,"version":"4.5.0"},"reference-count":160,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T00:00:00Z","timestamp":1606694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Myasthenia gravis (MG) is the most common autoimmune disorder affecting the neuromuscular junction, characterized by skeletal muscle weakness and fatigability. It is caused by autoantibodies targeting proteins of the neuromuscular junction; ~85% of MG patients have autoantibodies against the muscle acetylcholine receptor (AChR-MG), whereas about 5% of MG patients have autoantibodies against the muscle specific kinase (MuSK-MG). In the remaining about 10% of patients no autoantibodies can be found with the classical diagnostics for AChR and MuSK antibodies (seronegative MG, SN-MG). Since serological tests are relatively easy and non-invasive for disease diagnosis, the improvement of methods for the detection of known autoantibodies or the discovery of novel autoantibody specificities to diminish SN-MG and to facilitate differential diagnosis of similar diseases, is crucial. Radioimmunoprecipitation assays (RIPA) are the staple for MG antibody detection, but over the past years, using cell-based assays (CBAs) or improved highly sensitive RIPAs, it has been possible to detect autoantibodies in previously SN-MG patients. This led to the identification of more patients with antibodies to the classical antigens AChR and MuSK and to the third MG autoantigen, the low-density lipoprotein receptor-related protein 4 (LRP4), while antibodies against other extracellular or intracellular targets, such as agrin, K<jats:sub>v<\/jats:sub>1.4 potassium channels, collagen Q, titin, the ryanodine receptor and cortactin have been found in some MG patients. Since the autoantigen targeted determines in part the clinical manifestations, prognosis and response to treatment, serological tests are not only indispensable for initial diagnosis, but also for monitoring treatment efficacy. Importantly, knowing the autoantibody profile of MG patients could allow for more efficient personalized therapeutic approaches. Significant progress has been made over the past years toward the development of antigen-specific therapies, targeting only the specific immune cells or autoantibodies involved in the autoimmune response. In this review, we will present the progress made toward the development of novel sensitive autoantibody detection assays, the identification of new MG autoantigens, and the implications for improved antigen-specific therapeutics. These advancements increase our understanding of MG pathology and improve patient quality of life by providing faster, more accurate diagnosis and better disease management.<\/jats:p>","DOI":"10.3389\/fneur.2020.596981","type":"journal-article","created":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T06:33:38Z","timestamp":1606718018000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":117,"title":["Myasthenia Gravis: Autoantibody Specificities and Their Role in MG Management"],"prefix":"10.3389","volume":"11","author":[{"given":"Konstantinos","family":"Lazaridis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Socrates J.","family":"Tzartos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,11,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","article-title":"Myasthenia gravis - autoantibody characteristics and their implications for therapy","volume":"12","author":"Gilhus","year":"2016","journal-title":"Nat Rev Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.autrev.2013.03.001","article-title":"Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4","volume":"12","author":"Verschuuren","year":"2013","journal-title":"Autoimmun Rev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.conb.2005.12.003","article-title":"Assembly of the postsynaptic membrane at the neuromuscular junction: paradigm lost","volume":"16","author":"Kummer","year":"2006","journal-title":"Curr Opin Neurobiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/35097557","article-title":"Induction, assembly, maturation and maintenance of a postsynaptic apparatus","volume":"2","author":"Sanes","year":"2001","journal-title":"Nat Rev Neurosci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3389\/fimmu.2020.00212","article-title":"Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics","volume":"11","author":"Lazaridis","year":"2020","journal-title":"Front Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jaut.2013.12.011","article-title":"Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms","volume":"52","author":"Berrih-Aknin","year":"2014","journal-title":"J Autoimmun."},{"key":"B7","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers."},{"key":"B8","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2377-10-46","article-title":"A systematic review of population based epidemiological studies in Myasthenia Gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1084\/jem.144.3.739","article-title":"Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine receptor antibodies","volume":"144","author":"Lindstrom","year":"1976","journal-title":"J Exp Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e108327","DOI":"10.1371\/journal.pone.0108327","article-title":"Direct proof of the in vivo pathogenic role of the AChR autoantibodies from myasthenia gravis patients","volume":"9","author":"Kordas","year":"2014","journal-title":"PLoS ONE."},{"key":"B11","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S0140-6736(79)90823-7","article-title":"Long-term effects of repeated plasma exchange in myasthenia gravis","volume":"1","author":"Newsom-Davis","year":"1979","journal-title":"Lancet."},{"key":"B12","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/ana.21371","article-title":"Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction","volume":"63","author":"Cole","year":"2008","journal-title":"Ann Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"5190","DOI":"10.1172\/JCI66039","article-title":"Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis","volume":"123","author":"Shen","year":"2013","journal-title":"J Clin Invest."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1111\/j.1742-4658.2007.05935.x","article-title":"Muscle and neuronal nicotinic acetylcholine receptors. Structure, function and pathogenicity","volume":"274","author":"Kalamida","year":"2007","journal-title":"FEBS J."},{"key":"B15","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1073\/pnas.77.2.755","article-title":"Monoclonal antibodies used to probe acetylcholine receptor structure: localization of the main immunogenic region and detection of similarities between subunits","volume":"77","author":"Tzartos","year":"1980","journal-title":"Proc Natl Acad Sci USA."},{"key":"B16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1600-065X.1998.tb01190.x","article-title":"Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor","volume":"163","author":"Tzartos","year":"1998","journal-title":"Immunol Rev."},{"key":"B17","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s12031-009-9271-y","article-title":"Antigenic structure of the human muscle nicotinic acetylcholine receptor main immunogenic region","volume":"40","author":"Luo","year":"2010","journal-title":"J Mol Neurosci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jneuroim.2007.07.018","article-title":"Extracellular domains of the beta, gamma and epsilon subunits of the human acetylcholine receptor as immunoadsorbents for myasthenic autoantibodies: a combination of immunoadsorbents results in increased efficiency","volume":"190","author":"Kostelidou","year":"2007","journal-title":"J Neuroimmunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jneuroim.2008.06.020","article-title":"Towards antigen-specific apheresis of pathogenic autoantibodies as a further step in the treatment of myasthenia gravis by plasmapheresis","author":"Zisimopoulou","year":"2008","journal-title":"J Neuroimmunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/S0140-6736(95)92652-6","article-title":"Arthrogryposis multiplex congenita with maternal autoantibodies specific for a fetal antigen","volume":"346","author":"Vincent","year":"1995","journal-title":"Lancet."},{"key":"B21","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jaut.2013.12.008","article-title":"Clonal heterogeneity of thymic B cells from early-onset myasthenia gravis patients with antibodies against the acetylcholine receptor","volume":"52","author":"Vrolix","year":"2014","journal-title":"J Autoimmun."},{"key":"B22","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/j.1749-6632.1987.tb51301.x","article-title":"The membrane attack complex of complement at the endplate in myasthenia gravis","volume":"505","author":"Engel","year":"1987","journal-title":"Ann N Y Acad Sci."},{"key":"B23","first-page":"82","article-title":"Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3","volume":"67","author":"Rodgaard","year":"1987","journal-title":"Clin Exp Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJM197805182982004","article-title":"Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation","volume":"298","author":"Drachman","year":"1978","journal-title":"N Engl J Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1056\/NEJM198209233071301","article-title":"Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis","volume":"307","author":"Drachman","year":"1982","journal-title":"N Engl J Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/0022-510X(83)90096-5","article-title":"Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 2. Clinical and serological follow-up of individual patients","volume":"58","author":"Oosterhuis","year":"1983","journal-title":"J Neurol Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1586\/eci.12.34","article-title":"Muscle autoantibodies in myasthenia gravis: beyond diagnosis?","volume":"8","author":"Meriggioli","year":"2012","journal-title":"Expert Rev Clin Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jneuroim.2014.09.013","article-title":"Expression of extracellular domains of muscle specific kinase (MuSK) and use as immunoadsorbents for the development of an antigen-specific therapy","volume":"276","author":"Skriapa","year":"2014","journal-title":"J Neuroimmunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e80695","DOI":"10.1371\/journal.pone.0080695","article-title":"MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters","volume":"8","author":"Koneczny","year":"2013","journal-title":"PLoS ONE."},{"key":"B31","doi-asserted-by":"publisher","first-page":"20783","DOI":"10.1073\/pnas.1313944110","article-title":"MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4","volume":"110","author":"Huijbers","year":"2013","journal-title":"Proc Natl Acad Sci USA."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1212\/WNL.0b013e318237f660","article-title":"Anti-MuSK autoantibodies block binding of collagen Q to MuSK","volume":"77","author":"Kawakami","year":"2011","journal-title":"Neurology."},{"key":"B33","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3109\/08916930903555943","article-title":"Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction","volume":"43","author":"Gomez","year":"2010","journal-title":"Autoimmunity."},{"key":"B34","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaut.2016.11.005","article-title":"IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients","volume":"77","author":"Koneczny","year":"2017","journal-title":"J Autoimmun."},{"key":"B35","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1111\/j.1468-1331.2008.02176.x","article-title":"MuSK-positive myasthenia gravis is rare in the Polish population","volume":"15","author":"Kostera-Pruszczyk","year":"2008","journal-title":"Eur J Neurol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1136\/jnnp.2006.102517","article-title":"Epidemiology of myasthenia gravis with anti-muscle specific kinase antibodies in The Netherlands","volume":"78","author":"Niks","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1212\/01.WNL.0000065882.63904.53","article-title":"Clinical aspects of MuSK antibody positive seronegative MG","volume":"60","author":"Sanders","year":"2003","journal-title":"Neurology."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1097\/01.LAB.0000028144.48023.9B","article-title":"Anti-p110 autoantibodies identify a subtype of \u201cseronegative\u201d myasthenia gravis with prominent oculobulbar involvement","volume":"82","author":"Scuderi","year":"2002","journal-title":"Lab Invest."},{"key":"B39","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1111\/j.1468-1331.2009.02624.x","article-title":"Epidemiological and immunological profile of muscle-specific kinase myasthenia gravis in Greece","volume":"16","author":"Tsiamalos","year":"2009","journal-title":"Eur J Neurol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jneuroim.2010.10.023","article-title":"Clinical and immunological differences between early and late-onset myasthenia gravis in Japan","volume":"230","author":"Suzuki","year":"2011","journal-title":"J Neuroimmunol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jneuroim.2008.01.013","article-title":"Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1","volume":"195","author":"Niks","year":"2008","journal-title":"J Neuroimmunol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1212\/01.wnl.0000228225.23349.5d","article-title":"Anti-MuSK antibodies: correlation with myasthenia gravis severity","volume":"67","author":"Bartoccioni","year":"2006","journal-title":"Neurology."},{"key":"B43","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.cell.2008.10.002","article-title":"Lrp4 is a receptor for Agrin and forms a complex with MuSK","volume":"135","author":"Kim","year":"2008","journal-title":"Cell."},{"key":"B44","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis","volume":"69","author":"Higuchi","year":"2011","journal-title":"Ann Neurol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00415-011-6194-7","article-title":"Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis","volume":"259","author":"Pevzner","year":"2012","journal-title":"J Neurol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1001\/archneurol.2011.2393","article-title":"Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis","volume":"69","author":"Zhang","year":"2012","journal-title":"Arch Neurol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jaut.2013.12.004","article-title":"A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis","volume":"52","author":"Zisimopoulou","year":"2014","journal-title":"J Autoimmun."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1111\/ene.13979","article-title":"Clinical analysis of Chinese anti-low-density-lipoprotein-receptor-associated protein 4 antibodies in patients with myasthenia gravis","volume":"26","author":"Li","year":"2019","journal-title":"Eur J Neurol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1002\/mus.25591","article-title":"Anti-LRP4 autoantibodies in Chinese patients with myasthenia gravis","volume":"56","author":"Li","year":"2017","journal-title":"Muscle Nerve."},{"key":"B50","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/mus.25438","article-title":"Agrin and low-density lipoprotein-related receptor protein 4 antibodies in amyotrophic lateral sclerosis patients","volume":"55","author":"Rivner","year":"2017","journal-title":"Muscle Nerve."},{"key":"B51","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/acn3.26","article-title":"LRP4 antibodies in serum and CSF from amyotrophic lateral sclerosis patients","volume":"1","author":"Tzartos","year":"2014","journal-title":"Ann Clin Transl Neurol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s00415-017-8514-z","article-title":"Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis","volume":"264","author":"Cordts","year":"2017","journal-title":"J Neurol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/j.1749-6632.2012.06833.x","article-title":"The search for new antigenic targets in myasthenia gravis","volume":"1275","author":"Cossins","year":"2012","journal-title":"Ann N Y Acad Sci."},{"key":"B54","doi-asserted-by":"publisher","first-page":"e91816","DOI":"10.1371\/journal.pone.0091816","article-title":"Autoantibodies to agrin in myasthenia gravis patients","volume":"9","author":"Zhang","year":"2014","journal-title":"PLoS ONE."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1212\/WNL.0000000000000478","article-title":"Anti-agrin autoantibodies in myasthenia gravis","volume":"82","author":"Gasperi","year":"2014","journal-title":"Neurology."},{"key":"B56","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.neuroscience.2018.01.015","article-title":"Induction of anti-agrin antibodies causes myasthenia gravis in mice","volume":"373","author":"Yan","year":"2018","journal-title":"Neuroscience."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1007\/s00415-011-6344-y","article-title":"Anti-voltage-gated potassium channel Kv1.4 antibodies in myasthenia gravis","volume":"259","author":"Romi","year":"2012","journal-title":"J Neurol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/ene.12234","article-title":"Cardiac involvements in myasthenia gravis associated with anti-Kv1.4 antibodies","volume":"21","author":"Suzuki","year":"2014","journal-title":"Eur J Neurol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jneuroim.2005.08.017","article-title":"Novel autoantibodies to a voltage-gated potassium channel Kv1.4 in a severe form of myasthenia gravis","volume":"170","author":"Suzuki","year":"2005","journal-title":"J Neuroimmunol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1001\/archneurol.2009.229","article-title":"Autoimmune targets of heart and skeletal muscles in myasthenia gravis","volume":"66","author":"Suzuki","year":"2009","journal-title":"Arch Neurol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1083\/jcb.200307164","article-title":"MuSK is required for anchoring acetylcholinesterase at the neuromuscular junction","volume":"165","author":"Cartaud","year":"2004","journal-title":"J Cell Biol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1080\/08916930400021360","article-title":"The prevalence of anti-acetylcholinesterase antibodies in autoimmune disease","volume":"37","author":"Geen","year":"2004","journal-title":"Autoimmunity."},{"key":"B63","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1365-2249.1995.tb03674.x","article-title":"Antibodies to acetylcholinesterase cross-reacting with thyroglobulin in myasthenia gravis and Graves's disease","volume":"100","author":"Mappouras","year":"1995","journal-title":"Clin Exp Immunol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jneuroim.2009.11.004","article-title":"Anti-acetylcholinesterase antibodies associate with ocular myasthenia gravis","volume":"218","author":"Provenzano","year":"2010","journal-title":"J Neuroimmunol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jns.2014.12.015","article-title":"Collagen Q\u2013a potential target for autoantibodies in myasthenia gravis","volume":"348","author":"Zoltowska Katarzyna","year":"2015","journal-title":"J Neurol Sci."},{"key":"B66","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/mus.25969","article-title":"Autoimmune antibodies to collagen XIII in myasthenia gravis patients","volume":"57","author":"Tu","year":"2018","journal-title":"Muscle Nerve."},{"key":"B67","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/j.1365-2265.2004.02167.x","article-title":"Serum antibodies to collagen XIII: a further good marker of active Graves' ophthalmopathy","volume":"62","author":"De Bellis","year":"2005","journal-title":"Clin Endocrinol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1084\/jem.164.4.1043","article-title":"Thymic B lymphocyte clones from patients with myasthenia gravis secrete monoclonal striational autoantibodies reacting with myosin, alpha actinin, or actin","volume":"164","author":"Williams","year":"1986","journal-title":"J Exp Med."},{"key":"B69","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/j.1365-2249.1990.tb05440.x","article-title":"Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin","volume":"82","author":"Aarli","year":"1990","journal-title":"Clin Exp Immunol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1212\/WNL.37.8.1329","article-title":"Antifilamin, antivinculin, and antitropomyosin antibodies in myasthenia gravis","volume":"37","author":"Yamamoto","year":"1987","journal-title":"Neurology."},{"key":"B71","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1600-0404.2006.00608.x","article-title":"Titin and ryanodine receptor antibodies in myasthenia gravis","volume":"183","author":"Skeie","year":"2006","journal-title":"Acta Neurol Scand Suppl."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1161\/hh2301.100981","article-title":"The complete gene sequence of titin, expression of an unusual approximately 700-kDa titin isoform, and its interaction with obscurin identify a novel Z-line to I-band linking system","volume":"89","author":"Bang","year":"2001","journal-title":"Circ Res."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1212\/WNL.43.8.1581","article-title":"Titin antibodies in myasthenia gravis: identification of a major immunogenic region of titin","volume":"43","author":"Gautel","year":"1993","journal-title":"Neurology."},{"key":"B74","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1196\/annals.1405.040","article-title":"Myasthenia gravis in the elderly: is it different? Ann N Y Acad Sci","volume":"1132","author":"Aarli","year":"2008"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1212\/WNL.57.9.1579","article-title":"Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence?","volume":"57","author":"Buckley","year":"2001","journal-title":"Neurology."},{"key":"B76","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1001\/archneur.62.3.442","article-title":"Striational antibodies in myasthenia gravis: reactivity and possible clinical significance","volume":"62","author":"Romi","year":"2005","journal-title":"Arch Neurol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/ane.12271","article-title":"Antititin antibody in early- and late-onset myasthenia gravis","volume":"130","author":"Szczudlik","year":"2014","journal-title":"Acta Neurol Scand."},{"key":"B78","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1001\/archneur.58.6.885","article-title":"Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients","volume":"58","author":"Yamamoto","year":"2001","journal-title":"Arch Neurol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/j.1749-6632.1998.tb10978.x","article-title":"Anti-titin and antiryanodine receptor antibodies in myasthenia gravis patients with thymoma","volume":"841","author":"Baggi","year":"1998","journal-title":"Ann N Y Acad Sci."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1007\/s00415-004-0479-z","article-title":"The significance of titin antibodies in myasthenia gravis\u2013correlation with thymoma and severity of myasthenia gravis","volume":"251","author":"Chen","year":"2004","journal-title":"J Neurol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s004150050604","article-title":"Muscle autoantibodies in subgroups of myasthenia gravis patients","volume":"247","author":"Romi","year":"2000","journal-title":"J Neurol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/mus.23882","article-title":"Do acetylcholine receptor and striated muscle antibodies predict the presence of thymoma in patients with myasthenia gravis?","volume":"49","author":"Choi Decroos","year":"2014","journal-title":"Muscle Nerve."},{"key":"B83","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1212\/WNL.59.1.92","article-title":"The occurrence of anti-titin antibodies and thymomas: a population survey of MG 1970-1999","volume":"59","author":"Somnier","year":"2002","journal-title":"Neurology."},{"key":"B84","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jneuroim.2016.01.018","article-title":"Titin antibodies in \u201cseronegative\u201d myasthenia gravis\u2013a new role for an old antigen","volume":"292","author":"Stergiou","year":"2016","journal-title":"J Neuroimmunol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1212\/01.WNL.0000125254.99397.68","article-title":"Anti-ryanodine receptor antibodies and FK506 in myasthenia gravis","volume":"62","author":"Takamori","year":"2004","journal-title":"Neurology."},{"key":"B86","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/ana.410320419","article-title":"Ryanodine receptor autoantibodies in myasthenia gravis patients with a thymoma","volume":"32","author":"Mygland","year":"1992","journal-title":"Ann Neurol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/j.1468-1331.2007.01785.x","article-title":"Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features","volume":"14","author":"Romi","year":"2007","journal-title":"Eur J Neurol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/(SICI)1097-4598(199803)21:3<329::AID-MUS6>3.0.CO;2-C","article-title":"Myasthenia gravis sera containing antiryanodine receptor antibodies inhibit binding of [3H]-ryanodine to sarcoplasmic reticulum","volume":"21","author":"Skeie","year":"1998","journal-title":"Muscle Nerve."},{"key":"B89","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/377232a0","article-title":"Failure of postsynaptic specialization to develop at neuromuscular junctions of rapsyn-deficient mice","volume":"377","author":"Gautam","year":"1995","journal-title":"Nature."},{"key":"B90","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/j.1749-6632.1998.tb10972.x","article-title":"Rapsyn antibodies in myasthenia gravis","volume":"841","author":"Agius","year":"1998","journal-title":"Ann N Y Acad Sci."},{"key":"B91","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/j.1749-6632.1998.tb10974.x","article-title":"Antirapsyn antibodies occur commonly in patients with lupus","volume":"841","author":"Agius","year":"1998","journal-title":"Ann N Y Acad Sci."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1001\/jamaneurol.2016.2032","article-title":"Clinical characteristics of patients with double-seronegative myasthenia gravis and antibodies to cortactin","volume":"73","author":"Cortes-Vicente","year":"2016","journal-title":"JAMA Neurol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.autrev.2014.08.039","article-title":"Cortactin autoantibodies in myasthenia gravis","volume":"13","author":"Gallardo","year":"2014","journal-title":"Autoimmun Rev."},{"key":"B94","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/nyas.13502","article-title":"Diagnostic utility of cortactin antibodies in myasthenia gravis","volume":"1412","author":"Illa","year":"2018","journal-title":"Ann N Y Acad Sci."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.autrev.2014.08.038","article-title":"Identification of a novel myositis-associated antibody directed against cortactin","volume":"13","author":"Labrador-Horrillo","year":"2014","journal-title":"Autoimmun Rev."},{"key":"B96","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1001\/archneurol.2012.437","article-title":"Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis","volume":"69","author":"Jacob","year":"2012","journal-title":"Arch Neurol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.cccn.2005.05.035","article-title":"A sensitive non-isotopic assay for acetylcholine receptor autoantibodies","volume":"364","author":"Hewer","year":"2006","journal-title":"Clin Chim Acta."},{"key":"B98","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/j.1600-0404.1994.tb01626.x","article-title":"Detection of anti-acetylcholine receptor antibody by an ELISA using human receptor from a rhabdomyosarcoma cell line","volume":"89","author":"Martino","year":"1994","journal-title":"Acta Neurol Scand."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1093\/brain\/awn092","article-title":"IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis","volume":"131","author":"Leite","year":"2008","journal-title":"Brain."},{"key":"B100","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jneuroim.2015.04.015","article-title":"MuSK autoantibodies in myasthenia gravis detected by cell based assay\u2013a multinational study","volume":"284","author":"Tsonis","year":"2015","journal-title":"J Neuroimmunol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.1212\/NXI.0000000000000357","article-title":"IgG-specific cell-based assay detects potentially pathogenic MuSK-Abs in seronegative MG","volume":"4","author":"Huda","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B102","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/0090-1229(77)90027-7","article-title":"An assay for antibodies to human acetylcholine receptor in serum from patients with myasthenia gravis","volume":"7","author":"Lindstrom","year":"1977","journal-title":"Clin Immunol Immunopathol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"3334","DOI":"10.1073\/pnas.70.12.3334","article-title":"Studies on purified eel acetylcholine receptor and anti-acetylcholine receptor antibody","volume":"70","author":"Patrick","year":"1973","journal-title":"Proc Natl Acad Sci USA."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1212\/WNL.47.6.1552","article-title":"A transfected human muscle cell line expressing the adult subtype of the human muscle acetylcholine receptor for diagnostic assays in myasthenia gravis","volume":"47","author":"Beeson","year":"1996","journal-title":"Neurology."},{"key":"B105","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.nmd.2006.05.006","article-title":"A systematic review of diagnostic studies in myasthenia gravis","volume":"16","author":"Benatar","year":"2006","journal-title":"Neuromuscul Disord"},{"key":"B106","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.cccn.2004.05.008","article-title":"Muscle-specific receptor tyrosine kinase autoantibodies\u2013a new immunoprecipitation assay","volume":"348","author":"Matthews","year":"2004","journal-title":"Clin Chim Acta."},{"key":"B107","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1212\/01.WNL.0000129274.12702.92","article-title":"MuSK antibodies in AChR Ab-seropositive MG vs AChR Ab-seronegative MG","volume":"62","author":"Ohta","year":"2004","journal-title":"Neurology."},{"key":"B108","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/mus.23847","article-title":"Pure ocular anti-musk myasthenia under no immunosuppressive treatment","volume":"48","author":"Zouvelou","year":"2013","journal-title":"Muscle Nerve."},{"key":"B109","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/ene.13300","article-title":"Multiple antibody detection in 'seronegative' myasthenia gravis patients","volume":"24","author":"Hong","year":"2017","journal-title":"Eur J Neurol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jneuroim.2011.09.007","article-title":"Development of a highly sensitive diagnostic assay for muscle-specific tyrosine kinase (MuSK) autoantibodies in myasthenia gravis","author":"Trakas","year":"2011","journal-title":"J Neuroimmunol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.cca.2015.07.030","article-title":"An update on laboratory diagnosis in myasthenia gravis","volume":"449","author":"Oger","year":"2015","journal-title":"Clin Chim Acta."},{"key":"B112","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1002\/mus.20854","article-title":"Frequency of seronegativity in adult-acquired generalized myasthenia gravis","volume":"36","author":"Chan","year":"2007","journal-title":"Muscle Nerve."},{"key":"B113","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/j.1749-6632.1987.tb51321.x","article-title":"Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis","volume":"505","author":"Howard","year":"1987","journal-title":"Ann N Y Acad Sci."},{"key":"B114","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/mus.10294","article-title":"Ryanodine receptor antibodies in myasthenia gravis: epitope mapping and effect on calcium release in vitro","volume":"27","author":"Skeie","year":"2003","journal-title":"Muscle Nerve."},{"key":"B115","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jns.2010.10.023","article-title":"Non-radioactive serological diagnosis of myasthenia gravis and clinical features of patients from Tianjin, China","volume":"301","author":"Yang","year":"2011","journal-title":"J Neurol Sci."},{"key":"B116","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.nmd.2010.12.003","article-title":"Recombinant expression of the AChR-alpha1 subunit for the detection of conformation-dependent epitopes in Myasthenia Gravis","volume":"21","author":"Ching","year":"2011","journal-title":"Neuromuscul Disord."},{"key":"B117","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/ene.12270","article-title":"Antibodies to clustered acetylcholine receptor: expanding the phenotype","volume":"21","author":"Devic","year":"2014","journal-title":"Eur J Neurol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1001\/jamaneurol.2015.0203","article-title":"Clinical features and diagnostic usefulness of antibodies to clustered acetylcholine receptors in the diagnosis of seronegative myasthenia gravis","volume":"72","author":"Rodriguez Cruz","year":"2015","journal-title":"JAMA Neurol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/nyas.13592","article-title":"Serological and experimental studies in different forms of myasthenia gravis","volume":"1413","author":"Vincent","year":"2018","journal-title":"Ann N Y Acad Sci."},{"key":"B120","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jns.2014.05.037","article-title":"Clinical and serological study of myasthenia gravis using both radioimmunoprecipitation and cell-based assays in a South Asian population","volume":"343","author":"Chang","year":"","journal-title":"J Neurol Sci"},{"key":"B121","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.pediatrneurol.2019.01.016","article-title":"Cell-based versus enzyme-linked immunosorbent assay for the detection of acetylcholine receptor antibodies in Chinese juvenile myasthenia gravis","volume":"98","author":"Yan","year":"2019","journal-title":"Pediatr Neurol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s12264-012-1256-0","article-title":"Clinical significance of detection of antibodies to fetal and adult acetylcholine receptors in myasthenia gravis","volume":"28","author":"Shi","year":"2012","journal-title":"Neurosci Bull."},{"key":"B123","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1172\/JCI119048","article-title":"Association of arthrogryposis multiplex congenita with maternal antibodies inhibiting fetal acetylcholine receptor function","volume":"98","author":"Riemersma","year":"1996","journal-title":"J Clin Invest."},{"key":"B124","doi-asserted-by":"publisher","first-page":"14426","DOI":"10.1038\/s41598-017-14350-8","article-title":"Characterization of an anti-fetal AChR monoclonal antibody isolated from a myasthenia gravis patient","volume":"7","author":"Saxena","year":"2017","journal-title":"Sci Rep."},{"key":"B125","doi-asserted-by":"publisher","first-page":"577076","DOI":"10.1016\/j.jneuroim.2019.577076","article-title":"A novel MuSK cell-based myasthenia gravis diagnostic assay","volume":"337","author":"Han","year":"2019","journal-title":"J Neuroimmunol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"5284","DOI":"10.1038\/s41598-019-41730-z","article-title":"Cytometric cell-based assays for anti-striational antibodies in myasthenia gravis with myositis and\/or myocarditis","volume":"9","author":"Kufukihara","year":"2019","journal-title":"Sci Rep."},{"key":"B127","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jim.2018.06.016","article-title":"Immunostick ELISA for rapid and easy diagnosis of myasthenia gravis","volume":"460","author":"Trakas","year":"2018","journal-title":"J Immunol Methods."},{"key":"B128","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1093\/labmed\/lmy038","article-title":"A simple, rapid and non-radiolabeled immune assay to detect anti-achr antibodies in myasthenia gravis","volume":"50","author":"Bokoliya","year":"2019","journal-title":"Lab Med."},{"key":"B129","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1196\/annals.1405.012","article-title":"Response to therapy in myasthenia gravis with anti-MuSK antibodies","volume":"1132","author":"Evoli","year":"2008","journal-title":"Ann N Y Acad Sci."},{"key":"B130","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/mus.22006","article-title":"Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle Nerve."},{"key":"B131","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00415-014-7532-3","article-title":"Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis","volume":"262","author":"Iorio","year":"2015","journal-title":"J Neurol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/CND.0000000000000034","article-title":"Treatment-refractory myasthenia gravis","volume":"15","author":"Silvestri","year":"2014","journal-title":"J Clin Neuromuscul Dis."},{"key":"B133","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.3389\/fimmu.2019.03052","article-title":"Antagonism of the neonatal Fc receptor as an emerging treatment for myasthenia gravis","volume":"10","author":"Gable","year":"2019","journal-title":"Front Immunol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1080\/14656566.2019.1682548","article-title":"Current pharmacotherapeutic options for myasthenia gravis","volume":"20","author":"Barnett","year":"2019","journal-title":"Expert Opin Pharmacother."},{"key":"B135","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1749-6632.2012.06788.x","article-title":"Antigen-specific apheresis of autoantibodies in myasthenia gravis","volume":"1275","author":"Lazaridis","year":"2012","journal-title":"Ann N Y Acad Sci."},{"key":"B136","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ijbiomac.2013.11.003","article-title":"Expression of human AChR extracellular domain mutants with improved characteristics","volume":"63","author":"Lazaridis","year":"2014","journal-title":"Int J Biol Macromol."},{"key":"B137","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jneuroim.2014.12.001","article-title":"Specific adsorbents for myasthenia gravis autoantibodies using mutants of the muscle nicotinic acetylcholine receptor extracellular domains","volume":"278","author":"Lazaridis","year":"2015","journal-title":"J Neuroimmunol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"577136","DOI":"10.1016\/j.jneuroim.2019.577136","article-title":"Antigen-specific immunoadsorption of MuSK autoantibodies as a treatment of MuSK-induced experimental autoimmune myasthenia gravis","volume":"339","author":"Lazaridis","year":"2020","journal-title":"J Neuroimmunol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jneuroim.2017.09.001","article-title":"Specific removal of autoantibodies by extracorporeal immunoadsorption ameliorates experimental autoimmune myasthenia gravis","volume":"312","author":"Lazaridis","year":"2017","journal-title":"J Neuroimmunol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"8086","DOI":"10.1073\/pnas.96.14.8086","article-title":"Antigen-specific modulation of experimental myasthenia gravis: nasal tolerization with recombinant fragments of the human acetylcholine receptor alpha-subunit","volume":"96","author":"Barchan","year":"1999","journal-title":"Proc Natl Acad Sci USA."},{"key":"B141","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/j.1749-6632.1996.tb21134.x","article-title":"Oral tolerance in myasthenia gravis","volume":"778","author":"Drachman","year":"1996","journal-title":"Ann N Y Acad Sci."},{"key":"B142","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.bcp.2015.07.011","article-title":"AChR-specific immunosuppressive therapy of myasthenia gravis","volume":"97","author":"Luo","year":"2015","journal-title":"Biochem Pharmacol."},{"key":"B143","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/0165-5728(94)00187-S","article-title":"Suppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptor","volume":"58","author":"Ma","year":"1995","journal-title":"J Neuroimmunol."},{"key":"B144","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3389\/fimmu.2020.00403","article-title":"MuSK EAMG: immunological characterization and suppression by induction of oral tolerance","volume":"11","author":"Reuveni","year":"2020","journal-title":"Front Immunol."},{"key":"B145","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jneuroim.2004.04.010","article-title":"Immunosuppression of rat myasthenia gravis by oral administration of a syngeneic acetylcholine receptor fragment","volume":"152","author":"Maiti","year":"2004","journal-title":"J Neuroimmunol."},{"key":"B146","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.4049\/jimmunol.165.7.3599","article-title":"Role of tolerogen conformation in induction of oral tolerance in experimental autoimmune myasthenia gravis","volume":"165","author":"Im","year":"2000","journal-title":"J Immunol."},{"key":"B147","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.molimm.2008.08.264","article-title":"Suppression of experimental myasthenia gravis by a B-cell epitope-free recombinant acetylcholine receptor","volume":"46","author":"Yi","year":"2008","journal-title":"Mol Immunol."},{"key":"B148","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1172\/JCI7121","article-title":"Oral administration of an immunodominant T-cell epitope downregulates Th1\/Th2 cytokines and prevents experimental myasthenia gravis","volume":"104","author":"Baggi","year":"1999","journal-title":"J Clin Invest."},{"key":"B149","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.4049\/jimmunol.159.6.3016","article-title":"Tolerance to a dominant T cell epitope in the acetylcholine receptor molecule induces epitope spread and suppresses murine myasthenia gravis","volume":"159","author":"Wu","year":"1997","journal-title":"J Immunol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.3389\/fimmu.2017.01133","article-title":"A novel approach to reinstating tolerance in experimental autoimmune myasthenia gravis using a targeted fusion protein, mCTA1-T146","volume":"8","author":"Consonni","year":"2017","journal-title":"Front Immunol."},{"key":"B151","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1172\/JCI8121","article-title":"Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment","volume":"104","author":"Im","year":"1999","journal-title":"J Clin Invest."},{"key":"B152","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0165-5728(00)00395-7","article-title":"Mechanism of nasal tolerance induced by a recombinant fragment of acetylcholine receptor for treatment of experimental myasthenia gravis","volume":"111","author":"Im","year":"2000","journal-title":"J Neuroimmunol."},{"key":"B153","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/ana.410360504","article-title":"Oral administration of acetylcholine receptor: effects on experimental myasthenia gravis","volume":"36","author":"Okumura","year":"1994","journal-title":"Ann Neurol."},{"key":"B154","doi-asserted-by":"publisher","first-page":"7000","DOI":"10.1073\/pnas.90.15.7000","article-title":"Inhibition of T-cell reactivity to myasthenogenic epitopes of the human acetylcholine receptor by synthetic analogs","volume":"90","author":"Katz-Levy","year":"1993","journal-title":"Proc Natl Acad Sci USA."},{"key":"B155","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1073\/pnas.040554597","article-title":"Oral administration of a dual analog of two myasthenogenic T cell epitopes down-regulates experimental autoimmune myasthenia gravis in mice","volume":"97","author":"Paas-Rozner","year":"2000","journal-title":"Proc Natl Acad Sci USA."},{"key":"B156","doi-asserted-by":"publisher","first-page":"12642","DOI":"10.1073\/pnas.221456798","article-title":"The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routes","volume":"98","author":"Paas-Rozner","year":"2001","journal-title":"Proc Natl Acad Sci USA."},{"key":"B157","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jneuroim.2006.04.018","article-title":"Down-regulation of T cell responses to AChR and reversal of EAMG manifestations in mice by a dual altered peptide ligand via induction of CD4(+)CD25(+) regulatory cells","volume":"177","author":"Aruna","year":"2006","journal-title":"J Neuroimmunol"},{"key":"B158","doi-asserted-by":"publisher","first-page":"5044","DOI":"10.4049\/jimmunol.1401392","article-title":"Antigen-specific immunotherapeutic vaccine for experimental autoimmune myasthenia gravis","volume":"193","author":"Luo","year":"2014","journal-title":"J Immunol."},{"key":"B159","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1196\/annals.1405.007","article-title":"Myasthenia gravis and the tops and bottoms of AChRs: antigenic structure of the MIR and specific immunosuppression of EAMG using AChR cytoplasmic domains","volume":"1132","author":"Lindstrom","year":"2008","journal-title":"Ann N Y Acad Sci."},{"key":"B160","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/nyas.13550","article-title":"Acetylcholine receptor-specific immunosuppressive therapy of experimental autoimmune myasthenia gravis and myasthenia gravis","volume":"1413","author":"Luo","year":"2018","journal-title":"Ann N Y Acad Sci."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2020.596981\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T06:38:36Z","timestamp":1697265516000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2020.596981\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,30]]},"references-count":160,"alternative-id":["10.3389\/fneur.2020.596981"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2020.596981","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,30]]},"article-number":"596981"}}